They reported a 50% reduction in anti-MAG antibody titers in a patient described as having IgM MGUS with anti-MAG neuropathy [19]. There is currently an ongoing study, the MAGNAZ trial, which examines the combination of rituximab and zanubrutinib in treating polyneuropathy associated with anti-MAG antibodies [25]. Here, MAG is linked to neuropathy.